Stem Cell Therapy for Diabetes: Beta Cells versus Pancreatic Progenitors
<p dir="ltr">Diabetes mellitus (DM) is one of the most prevalent metabolic disorders. In order to replace the function of the destroyed pancreatic beta cells in diabetes, islet transplantation is the most widely practiced treatment. However, it has several limitations. As an alternat...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | |
| منشور في: |
2020
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1864513512280162304 |
|---|---|
| author | Bushra Memon (4792767) |
| author2 | Essam M. Abdelalim (5768072) |
| author2_role | author |
| author_facet | Bushra Memon (4792767) Essam M. Abdelalim (5768072) |
| author_role | author |
| dc.creator.none.fl_str_mv | Bushra Memon (4792767) Essam M. Abdelalim (5768072) |
| dc.date.none.fl_str_mv | 2020-01-23T06:00:00Z |
| dc.identifier.none.fl_str_mv | 10.3390/cells9020283 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/Stem_Cell_Therapy_for_Diabetes_Beta_Cells_versus_Pancreatic_Progenitors/26114485 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biological sciences Biochemistry and cell biology Biomedical and clinical sciences Clinical sciences Medical biotechnology hPSCs hyperglycemia insulin-secreting cells β-cell precursors pancreatic islets transplantation |
| dc.title.none.fl_str_mv | Stem Cell Therapy for Diabetes: Beta Cells versus Pancreatic Progenitors |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <p dir="ltr">Diabetes mellitus (DM) is one of the most prevalent metabolic disorders. In order to replace the function of the destroyed pancreatic beta cells in diabetes, islet transplantation is the most widely practiced treatment. However, it has several limitations. As an alternative approach, human pluripotent stem cells (hPSCs) can provide an unlimited source of pancreatic cells that have the ability to secrete insulin in response to a high blood glucose level. However, the determination of the appropriate pancreatic lineage candidate for the purpose of cell therapy for the treatment of diabetes is still debated. While hPSC-derived beta cells are perceived as the ultimate candidate, their efficiency needs further improvement in order to obtain a sufficient number of glucose responsive beta cells for transplantation therapy. On the other hand, hPSC-derived pancreatic progenitors can be efficiently generated in vitro and can further mature into glucose responsive beta cells in vivo after transplantation. Herein, we discuss the advantages and predicted challenges associated with the use of each of the two pancreatic lineage products for diabetes cell therapy. Furthermore, we address the co-generation of functionally relevant islet cell subpopulations and structural properties contributing to the glucose responsiveness of beta cells, as well as the available encapsulation technology for these cells.</p><h2>Other Information</h2><p dir="ltr">Published in: Cells<br>License: <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank">https://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.3390/cells9020283" target="_blank">https://dx.doi.org/10.3390/cells9020283</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_20f752ce7082b702d4a933e959696b71 |
| identifier_str_mv | 10.3390/cells9020283 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/26114485 |
| publishDate | 2020 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Stem Cell Therapy for Diabetes: Beta Cells versus Pancreatic ProgenitorsBushra Memon (4792767)Essam M. Abdelalim (5768072)Biological sciencesBiochemistry and cell biologyBiomedical and clinical sciencesClinical sciencesMedical biotechnologyhPSCshyperglycemiainsulin-secreting cellsβ-cell precursorspancreatic isletstransplantation<p dir="ltr">Diabetes mellitus (DM) is one of the most prevalent metabolic disorders. In order to replace the function of the destroyed pancreatic beta cells in diabetes, islet transplantation is the most widely practiced treatment. However, it has several limitations. As an alternative approach, human pluripotent stem cells (hPSCs) can provide an unlimited source of pancreatic cells that have the ability to secrete insulin in response to a high blood glucose level. However, the determination of the appropriate pancreatic lineage candidate for the purpose of cell therapy for the treatment of diabetes is still debated. While hPSC-derived beta cells are perceived as the ultimate candidate, their efficiency needs further improvement in order to obtain a sufficient number of glucose responsive beta cells for transplantation therapy. On the other hand, hPSC-derived pancreatic progenitors can be efficiently generated in vitro and can further mature into glucose responsive beta cells in vivo after transplantation. Herein, we discuss the advantages and predicted challenges associated with the use of each of the two pancreatic lineage products for diabetes cell therapy. Furthermore, we address the co-generation of functionally relevant islet cell subpopulations and structural properties contributing to the glucose responsiveness of beta cells, as well as the available encapsulation technology for these cells.</p><h2>Other Information</h2><p dir="ltr">Published in: Cells<br>License: <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank">https://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.3390/cells9020283" target="_blank">https://dx.doi.org/10.3390/cells9020283</a></p>2020-01-23T06:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.3390/cells9020283https://figshare.com/articles/journal_contribution/Stem_Cell_Therapy_for_Diabetes_Beta_Cells_versus_Pancreatic_Progenitors/26114485CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/261144852020-01-23T06:00:00Z |
| spellingShingle | Stem Cell Therapy for Diabetes: Beta Cells versus Pancreatic Progenitors Bushra Memon (4792767) Biological sciences Biochemistry and cell biology Biomedical and clinical sciences Clinical sciences Medical biotechnology hPSCs hyperglycemia insulin-secreting cells β-cell precursors pancreatic islets transplantation |
| status_str | publishedVersion |
| title | Stem Cell Therapy for Diabetes: Beta Cells versus Pancreatic Progenitors |
| title_full | Stem Cell Therapy for Diabetes: Beta Cells versus Pancreatic Progenitors |
| title_fullStr | Stem Cell Therapy for Diabetes: Beta Cells versus Pancreatic Progenitors |
| title_full_unstemmed | Stem Cell Therapy for Diabetes: Beta Cells versus Pancreatic Progenitors |
| title_short | Stem Cell Therapy for Diabetes: Beta Cells versus Pancreatic Progenitors |
| title_sort | Stem Cell Therapy for Diabetes: Beta Cells versus Pancreatic Progenitors |
| topic | Biological sciences Biochemistry and cell biology Biomedical and clinical sciences Clinical sciences Medical biotechnology hPSCs hyperglycemia insulin-secreting cells β-cell precursors pancreatic islets transplantation |